Bowen MD, Peters CJ, Nichol ST, 1997. Phylogenetic analysis of theArenaviridae:patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol Phylogenet Evol 8: 301–316.
WHO, 2017. Lassa Fever. Available at: https://www.who.int/news-room/fact-sheets/detail/lassa-fever. Accessed November 26, 2019.
Kernéis S, Koivogui L, Magassouba N, Koulemou K, Lewis R, Aplogan A, Grais RF, Guerin PJ, Elisabeth F, 2009. Prevalence and risk factors of Lassa seropositivity in inhabitants of the forest region of Guinea: a cross-sectional study. PLoS Negl Trop Dis 3: e548.
Ilori EA 2019. Epidemiologic and clinical features of Lassa fever outbreak in Nigeria, January 1–May 6, 2018. Emerg Infect Dis 25: 1066–1074.
Günther S, Lenz O, 2004. Lassa virus. Crit Rev Clin Lab Sci 41: 339–390.
Frame JD Jr., Baldwin MB, Gocke DJ, Troup JM, 1970. Lassa fever, a new virus disease of man from West Africa. Am J Trop Med Hyg 19: 670–676.
Yakubu B, Longdet IY, Tony HJ, Davou DT, Obishakin E, 2019. High-complexity Plasmodium falciparum infections, north Central Nigeria, 2015–2018. Emerg Infect Dis 25: 1330–1338.
Olayiwola J, Bakarey A, 2017. Epidemiological trends of Lassa fever outbreaks and insights for future control in Nigeria. Int J Trop Dis Health 24: 1–14.
NCDC, 2018. Nigeria Centre for Disease Control. An Update of Lassa Fever Outbreak in Nigeria. Available at: https://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An%20update%20of%20Lassa%20fever%20outbreak%20in%20Nigeria. Accessed December 19, 2018.
Monath TP, Mertens PE, Patton R, Moser CR, Pineo L, Gary GW, Kissling RE, 1973. A hospital epidemic of Lassa fever in Zorzor, Liberia, March–April 1972. Am J Trop Med Hyg 22: 773–779.
Mertens PE, Patton R, Baum JJ, Monath TP, 1972. Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March–April 1972. Am J Trop Med Hyg 22: 780–784.
Fraser DW, Campbell CC, Monath TP, Goff PA, Gregg MB, 1974. Lassa fever in the eastern province of Sierra Leone, 1970–1972. I. Epidemiologic studies. Am J Trop Med Hyg 23: 1131–1139.
Monath TP, Maher M, Casals J, Kissling RE, Cacciapuoti A, 1974. Lassa fever in the eastern province of Sierra Leone, 1970–1972. II. Clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg 23: 1140–1149.
Research Gate, 2014. Lassa Fever in Post-Conflict Sierra Leone. Available at: https://www.researchgate.net/publication/261513808_Lassa_Fever_in_Post-Conflict_Sierra_Leone. Accessed November 28, 2019.
Wulff H, McIntosh BM, Hamner DB, Johnson KM, 1977. Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa. Bull World Health Organ 55: 441–444.
Johnson KM, Taylor P, Elliott LH, Tomori O, 1981. Recovery of a Lassa-related arenavirus in Zimbabwe. Am J Trop Med Hyg 30: 1291–1293.
Briese T 2009. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever–associated arenavirus from southern Africa. PLoS Pathog 5: e1000455.
Paweska JT Outbreak Control and Investigation Teams, 2009. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis 15: 1598–1602.
Gonzalez JP, McCormick JB, Saluzzo JF, Herve JP, Johnson KM, Georges AJ, 1983. An Arenavirus isolated from wild-caught rodents (Praomys species) in the Central African Republic. Intervirology 19: 105–112.
Swanepoel R, Leman PA, Shepherd AJ, Shepherd SP, Kiley MD, McCormick JB, 1985. Identification of Ippy as a Lassa-fever-related virus. Lancet 1: 639.
Patassi AA 2017. Emergence of Lassa fever disease in northern Togo: report of two cases in Oti district in 2016. Case Rep Infect Dis 2017: 8242313.
Morse SS, 1995. Factors in the emergence of infectious diseases. Emerg Infect Dis 1: 1–15.
Davis JR, Lederberg J, 2000. Infections I of M (US) F on E, Introduction. Washington, DC: National Academies Press. Available at: https://www.ncbi.nlm.nih.gov/books/NBK100258/. Accessed November 29, 2019.
Morse SS, 1997. The public health threat of emerging viral disease. J Nutr 127: 951S–957S.
United States, Department of State, Bureau of Public Affairs, Nigeria, 1987. Department of State Publication. Background Notes Series. Washington, DC: Government Printing Office.
Scott-Emuakpor A, 2010. The evolution of health care systems in Nigeria: which way forward in the twenty-first century. Niger Med J 51: 53–65.
Butler CD, 2012. Infectious disease emergence and global change: thinking systemically in a shrinking world. Infect Dis Poverty 1: 5.
Tambo E, Adetunde OT, Olalubi OA, 2018. Re-emerging Lassa fever outbreaks in Nigeria: re-enforcing “One Health” community surveillance and emergency response practice. Infect Dis Poverty 7: 37.
Fall IS 2019. Integrated Disease Surveillance and Response (IDSR) strategy: current status, challenges and perspectives for the future in Africa. BMJ Glob Health 4: e001427.
Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand S, Djingarey MH, Olson V, Damon IK, Khalakdina A, 2018. Emergence of monkeypox — west and central Africa, 1970–2017. MMWR Morb Mortal Wkly Rep 67: 306–310.
Saez AM, Haidara MC, Camara A, Kourouma F, Sage M, Magassouba N, Fichet-Calvet E, 2018. Rodent control to fight Lassa fever: evaluation and lessons learned from a 4-year study in upper Guinea. PLoS Negl Trop Dis 12: e0006829.
Iacono GL 2015. Using modelling to disentangle the relative contributions of zoonotic and anthroponotic transmission: the case of Lassa fever. PLoS Negl Trop Dis 9: e3398.
Gibb R, Moses LM, Redding DW, Jones KE, 2017. Understanding the cryptic nature of Lassa fever in west Africa. Pathog Glob Health 111: 276–288.
Fisher-Hoch SP, 2005. Lessons from nosocomial viral haemorrhagic fever outbreaks. Br Med Bul 73–74: 123–137.
Gayer M, Legros D, Formenty P, Connolly MA, 2007. Conflict and emerging infectious diseases. Emerg Infect Dis 13: 1625–1631.
Lalis A, Leblois R, Lecompte E, Denys C, Meulen J, Wirth T, 2012. The impact of human conflict on the genetics of Mastomys natalensis and Lassa virus in west Africa. PLoS One 7: e37068.
Richmond JK, Baglole DJ, 2003. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 327: 1271–1275.
Keïta M 2019. Investigation of a cross-border case of Lassa fever in West Africa. BMC Infect Dis 19: 606.
Mazzola LT, Kelly-Cirino C, 2019. Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings. BMJ Glob Health 4 (Suppl 2): e001116.
Knippertz P, Fink AH, 2008. Dry-season precipitation in tropical west Africa and its relation to forcing from the extratropics. Mon Weather Rev 136: 3579–3596.
Massawe AW, Makundi RH, Zhang Z, Mamphi G, Liu M, Li H, Belmain S, 2018. Effect of synthetic hormones on reproduction in Mastomys natalensis. J Pest Sci 91: 157–168.
Akhmetzhanov AR, Asai Y, Nishiura H, 2019. Quantifying the seasonal drivers of transmission for Lassa fever in Nigeria. Philos Trans R Soc B Biol Sci 374: 20180268.
Fichet-Calvet E, Lecompte E, Koivogui L, Soropogui B, Dore A, Kourouma, Sylla O, Daffis S, Koulemou K, Meulen J, 2007. Fluctuation of abundance and Lassa virus prevalence in Mastomys natalensis in Guinea, West Africa. Vector Borne Zoonotic Dis Larchmt N 7: 119–128.
Kajero O, Del Rio Vilas V, Wood JLN, Lo Iacono G, 2019. New methodologies for the estimation of population vulnerability to diseases: a case study of Lassa fever and Ebola in Nigeria and Sierra Leone. Philos Trans R Soc B Biol Sci 374: 20180265.
Brown H, Kelly AH, 2014. Material proximities and hotspots: toward an anthropology of viral hemorrhagic fevers. Med Anthropol Q 28: 280–303.
Wilkinson A, 2017. Emerging disease or emerging diagnosis?: Lassa fever and ebola in Sierra Leone. Anthropol Q 90: 369–397.
CDC, 2019. Graphics | Multimedia | NCEZID | CDC. Available at: https://www.cdc.gov/ncezid/multimedia/graphics.html. Accessed December 3, 2019.
Hussain-Alkhateeb L 2018. Early warning and response system (EWARS) for dengue outbreaks: recent advancements towards widespread applications in critical settings. PLoS One 13: e0196811.
McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliot LH, Belmont-Williams R, 1986. Lassa fever. Effective therapy with ribavirin. N Engl J Med 314: 20–26.
Geisbert TW 2005. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2: e183.
Gouglas D, Christodoulou M, Plotkin SA, Hatchett R, 2019. CEPI: driving progress towards epidemic preparedness and response. Epidemiol Rev 41: 28–33.
NIH, 2019. Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers - Full Text View - ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03805984. Accessed December 2, 2019.
Purushotham J, Lambe T, Gilbert SC, 2019. Vaccine platforms for the prevention of Lassa fever. Immunol Lett 215: 1–11.
NIH, 2019. Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants - Full Text View - ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03993704. Accessed September 29, 2020.
Lassa fever remains endemic in parts of West Africa and continues to pose as a quiescent threat globally. We described the background on Lassa fever, factors contributing to its emergence and spread, preventive measures, and potential solutions. This review provides a holistic and comprehensive source for academicians, clinicians, researchers, policymakers, infectious disease epidemiologists, virologists, and other stakeholders.
Authors’ addresses: Oluwafemi O. Balogun, Massachusetts Department of Public Health, Bureau of Infectious Diseases and Laboratory Services, Office of Integrated Surveillance and Informatics Services, Boston, MA, and Department of Global Health, Boston University School of Public Health, Boston, MA, E-mail: oluwafemi.o.balogun@mass.gov. Oluwatosin W. Akande, Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, Ilorin, Nigeria, E-mail: akande.wuraola@gmail.com. Davidson H. Hamer, Infectious Diseases, Boston University Medical Campus, Boston, MA, and Global Health and Infectious Disease, Boston University School of Public Health, Boston, MA, E-mail: dhamer@bu.edu.